Skip to content
Screener

Reported November 4, 2026 · Before market open

Revenue-Miss by $7.1K
EPS-$0.84Beat by $0.34
Revenue estimate$7.1K
EPS estimate-$1.18
“We continue to deliver on our priorities with strong execution across the portfolio. Our positive Phase 2 results in bipolar mania are transformational for Rapport, accelerating our path to becoming an industry-leading precision neuroscience company. RAP-219 now has clinical proof-of-concept in two indications across neurology and psychiatry, giving us the opportunity to serve patients in two multibillion-dollar markets. We are building on this momentum, with a steady cadence of catalysts ahead. With the additional capital from our recent financing, we are well funded to deliver on the catalysts ahead and remain committed to delivering sustained value for both patients and shareholders.”
Abraham N. Ceesay

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue-—
Operating income-$44.1M-47.0%
Net income-$40.2M-49.4%
EPS (diluted)-$0.84-18.3%

Balance sheet

See full
Cash & equivalents$74.8M-70.3%
Total debt$9.4M-20.9%
Total equity$391.2M-23.5%
Total assets$418.6M-21.8%

Cash flow

See full
Operating cash flow-$41.6M-138%
Free cash flow-$41.6M-137%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$1.55B+30.1%
Enterprise value$1.48B+56.1%

Returns & leverage

See full
Return on equity-33.3%+24.5pp
Debt / equity0×0.0×
Current ratio20.1×-16.3×

FAQ

When did Rapport Therapeutics, Inc. report Q3 2026 earnings?
Rapport Therapeutics, Inc. (RAPP) reported Q3 2026 earnings on November 4, 2026 before market open.
What were Rapport Therapeutics, Inc.'s Q3 2026 revenue and EPS?
Rapport Therapeutics, Inc. reported revenue of - and eps of $-0.84 for Q3 2026.
Did Rapport Therapeutics, Inc. beat estimates in Q3 2026?
Revenue missed the consensus estimate of $7.1K by $7.1K. EPS beat the consensus estimate of $-1.18 by $0.34.
How did Rapport Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 18.3% from $-0.71.
Where can I find Rapport Therapeutics, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-446202) and the 10-Q periodic report (0001193125-26-446217) directly on SEC EDGAR. The filing index links above go to sec.gov.